Albany Molecular Research Inc (AMRI) Files Form 4 Insider Selling : Kevin Oconnor Sells 5,000 Shares

Albany Molecular Research Inc (AMRI): Kevin Oconnor , director of Albany Molecular Research Inc sold 5,000 shares on May 31, 2016. The Insider selling transaction was reported by the company on Jun 1, 2016 to the Securities and Exchange Commission. The shares were sold at $14.41 per share for a total value of $72,050.00 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on May 16, 2016, Steven R Hagen (SVP Manufacturing & Pharmaceut) sold 2,361 shares at $12.77 per share price.On May 16, 2016, George Svokos (COO) purchased 12,500 shares at $12.82 per share price.Also, On May 16, 2016, William S Marth (CEO) purchased 12,500 shares at $12.86 per share price.On Nov 10, 2015, Ambra Constance M D (10% owner) sold 50,000 shares at $19.60 per share price.

Albany Molecular Research: On Wednesday, Jun 1, 2016 heightened volatility was witnessed in Albany Molecular Research which led to swings in the share price. The shares opened for trading at $14.53 and hit $14.9 on the upside , eventually ending the session at $14.82, with a gain of 2.07% or 0.3 points. The heightened volatility saw the trading volume jump to 1,82,443 shares. The 52-week high of the share price is $22.48 and the company has a market cap of $529 M . The 52-week low of the share price is at $12.45.

Albany Molecular Research Money Flow Index Chart

Albany Molecular Research Inc. is a global contract research and manufacturing organization providing drug discovery development and manufacturing services. The Company operates in three business segments: Discovery and Development Services (DDS) API and Drug Product. The Company offers a portfolio of services from target identification tools to investigational new drug (IND) enabling activities. The Company’s manufacturing facilities are situated in various locations in the United States Europe and Asia. The Company provides state-of-the-art facilities and solutions to deliver integrated pharmaceutical drug development programs and services including process research and development pre-formulation and formulation development good laboratory practices (GLP) bioanalytical and separation sciences.

Leave a Reply

Albany Molecular Research - Is it time to Sell?

Top Brokerage Firms are advising their investors on Albany Molecular Research. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.